Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP758889.RAcqjpbp2NPQa2YgKtuiLjiOC72VTrhKBhseS6aYFX64E130_assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP758889.RAcqjpbp2NPQa2YgKtuiLjiOC72VTrhKBhseS6aYFX64E130_provenance.
• assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP852311.RAh7kIB8Y6Ey6OowLu-29xck4OKVgA7hLMyl1-5GBQhC4130_assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP852311.RAh7kIB8Y6Ey6OowLu-29xck4OKVgA7hLMyl1-5GBQhC4130_provenance.
• NP852314.RAnHf4P65PQIZqYSZ_xUrn104cwbEtOC4aVLVtKbMwK_U130_assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP852314.RAnHf4P65PQIZqYSZ_xUrn104cwbEtOC4aVLVtKbMwK_U130_provenance.
• NP758689.RAPvLM6sUtFWfwDxK9Huq6Ez2CskjX-CnFPDy9Xg-JMeU130_assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP758689.RAPvLM6sUtFWfwDxK9Huq6Ez2CskjX-CnFPDy9Xg-JMeU130_provenance.
• NP758885.RA6kFPP3ldXSM2NqKke-ToAB8a77SEKXxb90SoTnMIRT0130_assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP758885.RA6kFPP3ldXSM2NqKke-ToAB8a77SEKXxb90SoTnMIRT0130_provenance.
• NP759522.RA_niRRhNpB5e6gnKm41XCcMvKGF2v6HOoWn2qiNzMN6s130_assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP759522.RA_niRRhNpB5e6gnKm41XCcMvKGF2v6HOoWn2qiNzMN6s130_provenance.
• NP759819.RA0ukbQkJoaVPNfmfdr7qxPNl_rg7o2vFbWyOwj2JHdVQ130_assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP759819.RA0ukbQkJoaVPNfmfdr7qxPNl_rg7o2vFbWyOwj2JHdVQ130_provenance.
• NP852313.RAOHrZFkEA1QsEh6gkBmL-KqR96ECw52nQyc0_pNkSwx0130_assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP852313.RAOHrZFkEA1QsEh6gkBmL-KqR96ECw52nQyc0_pNkSwx0130_provenance.
• NP852307.RA-2oRqS0-DJ3o7-t6Wj1nS_EhBLKLLbXZCQrKgTyzuEg130_assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP852307.RA-2oRqS0-DJ3o7-t6Wj1nS_EhBLKLLbXZCQrKgTyzuEg130_provenance.
• NP852309.RA3t5_VAu5NZAt5kKZ3oJ1sbapGK7cAaGbrrws6TMvT0k130_assertion description "[We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP852309.RA3t5_VAu5NZAt5kKZ3oJ1sbapGK7cAaGbrrws6TMvT0k130_provenance.